Bruker Announces Key Innovations for Highly Multiplexed Spatial Proteomics and Multiomic Tissue Imaging at Large Field-of-View
June 06 2022 - 6:00AM
Business Wire
- Fast, large field-of-view MALDI HiPLEX-IHC imaging of
targeted proteins, overlaid with unbiased small molecule MALDI
Imaging on fresh frozen or FFPE tissues offers compelling
innovation for spatial biology and cancer research
- New microGRID technology for timsTOF fleX platform for MALDI
positioning provides virtually artifact-free images across entire
slide down to 5 µm
- SCiLS™ Lab 2023a software demonstrates advanced imaging
analysis with 4D Feature-Finder for CCS-enabled imaging and
multiomics capabilities, combining, e.g., protein, glycan and lipid
images from same tissue section
At the 70th ASMS Conference, Bruker Corporation (Nasdaq: BRKR)
announced key innovations for spatial multiomics of tissue and
tumor microenvironments (TME). Following Bruker’s strategic
partnership with AmberGen1, key enhancements are introduced for
MALDI HiPLEX-IHC mass spectrometry imaging.
This press release features multimedia. View
the full release here:
https://www.businesswire.com/news/home/20220606005370/en/
Images from a single fresh-frozen
sagittal mouse brain section showing three representative lipids
associated with neurological function, three of the 12plex targeted
neurological proteins from the MALDI HiPLEX-IHC experiment on the
same tissue section, and a true multiomic overlay of a
representative lipid and two proteins. Images were rendered using
the new multiomic module for SCiLS Lab 2023a. (Photo: Business
Wire)
MALDI HiPLEX-IHC represents a breakthrough in multiomics
imaging by combining targeted protein expression spatial profiling
with unbiased small molecule MALDI Imaging to co-localize proteins
and small molecules such as glycans, lipids, metabolites, or
xenobiotics. Using AmberGen’s MiralysTM antibody-based
photocleavable peptide mass tags, highly multiplexed IHC staining
and photocleavage of peptide markers fit seamlessly into Bruker’s
IntelliSlide®-based automated workflows for MALDI imaging.
Novel multiomic imaging enhances spatial high-plex protein
imaging with the ability to elucidate metabolic processes in the
same tissue section. In addition to mapping tens to over one
hundred targeted proteins with high-plex peptide tags, MALDI
HiPLEX-IHC can track signaling pathways such as glycosylation,
observe lipid spatial profiles for tumor microenvironment
segmentation, or simultaneously observe how drugs affect both
protein and metabolic states.
Dr. Peggi Angel, Professor of Cell and Molecular Pharmacology
and Experimental Therapeutics at the Medical University of South
Carolina commented: “From the perspective of a lab heavily invested
in cellular signaling processes in cancer biology, MALDI
HiPLEX-IHC is a game changer allowing integration of mass
spectrometry imaging with cell biology. We will be using this
technology for multiomic N-glycan and collagen imaging studies to
understand aggressive breast cancers. I expect that researchers
investigating the tissue microenvironment will quickly adopt this
unique spatial multiomics technology.”
Bruker also announced its microGRID module for smartbeam
3D MALDI sources for timsTOF fleX systems. The microGRID
improves the MALDI stage to sub-micron precision to correct laser
positioning on tissue surfaces down to 5 micrometers (µm),
virtually eliminating any visual artifacts or artifacts in
co-registration of MALDI images with optical microscopy. As
correction is effective for entire pathology slides,
microGRID leverages a large field-of-view for MALDI
HiPLEX-IHC protein expression profiling.
Dr. Ron Heeren, Distinguished Professor and Limburg co-chair of
the Maastricht Multimodal Molecular Imaging (M4I) Institute, added:
“At M4I, we develop workflows and techniques to contextualize the
role of individual cells in disease, and determine how interactions
between cells affects cellular states locally and across long
distances.”
Dr. Heeren continued: “Since we work closely with pathologists
and cancer researchers who are used to microscopes, we cannot
afford artifacts in our mass spectrometry images, and need large
fields-of-view. Bruker’s microGRID achieves this effortlessly
without limiting the area of the slide we can process for
multiomic, multimodal images of diseased and homeostatic
pathology.”
Bruker also demonstrated key updates for MALDI Imaging data
analysis using SCiLSTM Lab 2023a, including microGRID
support and improvements in handling CCS (collisional cross
section)-enabled imaging datasets acquired with timsTOF technology.
SCiLSTM Lab 2023a introduces the novel 4D Feature-Finder for
visualizing CCS-resolved features in intuitive mass-mobility
diagrams. In addition, images produced from multimodal datasets
were demonstrated with MALDI HiPLEX-IHC protein expression
spatial profiling. This allows SCiLS Lab to leverage its
auto-segmentation and statistical profiling tools using images that
overlay protein and small molecule localization on the same tissue
section.
About Bruker Corporation (Nasdaq: BRKR)
Bruker is enabling scientists to make breakthrough discoveries
and develop new applications that improve the quality of human
life. Bruker’s high performance scientific instruments and high
value analytical and diagnostic solutions enable scientists to
explore life and materials at molecular, cellular and microscopic
levels. In close cooperation with our customers, Bruker is enabling
innovation, improved productivity and customer success in life
science molecular and cell biology research, in applied and pharma
applications, in microscopy and nanoanalysis, as well as in
industrial applications. Bruker offers differentiated, high-value
life science and diagnostics systems and solutions in preclinical
imaging, clinical phenomics research, proteomics and multiomics,
spatial and single-cell biology, functional structural and
condensate biology, as well as in clinical microbiology and
molecular diagnostics. Please visit www.bruker.com.
______________________________________ 1
https://www.businesswire.com/news/home/20220411005644/en/
View source
version on businesswire.com: https://www.businesswire.com/news/home/20220606005370/en/
Media Petra Scheffer Bruker Daltonics Marketing
Communications T: +49 (421) 2205-2843 E:
petra.scheffer@bruker.com
Investor Relations Justin Ward Sr. Director Investor
Relations & Corp Development T: +1 (978) 663–3660, ext. 1479 E:
Investor.Relations@bruker.com
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jun 2024 to Jul 2024
Bruker (NASDAQ:BRKR)
Historical Stock Chart
From Jul 2023 to Jul 2024